Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Serguei, Nabirotchkin"'
Autor:
Serguei, Nabirotchkin, Jan, Bouaziz, Fabrice, Glibert, Jonas, Mandel, Julie, Foucquier, Rodolphe, Hajj, Noëlle, Callizot, Nathalie, Cholet, Mickaël, Guedj, Daniel, Cohen
Publikováno v:
Journal of Alzheimer's Disease. 88:1585-1603
Background: Human diseases are multi-factorial biological phenomena resulting from perturbations of numerous functional networks. The complex nature of human diseases explains frequently observed marginal or transitory efficacy of mono-therapeutic in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3689c941909510a2251ed0bd5d8421b6
https://doi.org/10.3233/jad-220120
https://doi.org/10.3233/jad-220120
Autor:
Thomas Prukop, Jan Stenzel, Stephanie Wernick, Theresa Kungl, Magdalena Mroczek, Julia Adam, David Ewers, Serguei Nabirotchkin, Klaus-Armin Nave, Rodolphe Hajj, Daniel Cohen, Michael W Sereda
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0209752 (2019)
The most common type of Charcot-Marie-Tooth disease is caused by a duplication of PMP22 leading to dysmyelination, axonal loss and progressive muscle weakness (CMT1A). Currently, no approved therapy is available for CMT1A patients. A novel polytherap
Externí odkaz:
https://doaj.org/article/54beea3e92d54d269e68e88861e3c885
Autor:
Julien Laffaire, Serguei Nabirotchkin, Noelle Callizot, Philippe Rinaudo, Peter Schmitt, Daniel Cohen, Lydie Boussicault, Rodolphe Hajj
Publikováno v:
Journal of Neuroscience Research
There is currently no therapy impacting the course of amyotrophic lateral sclerosis (ALS). The only approved treatments are riluzole and edaravone, but their efficacy is modest and short‐lasting, highlighting the need for innovative therapies. We p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54574081e684e3891ff9d7410666c3df
https://doi.org/10.1002/jnr.24714
https://doi.org/10.1002/jnr.24714
Autor:
Julien Laffaire, Rodolphe Hajj, Noelle Callizot, Lydie Boussicault, Philippe Rinaudo, Peter Schmitt, Daniel Cohen, Serguei Nabirotchkin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68df2cac72ce99448ab658c6c432f971
https://doi.org/10.1002/jnr.24714/v2/response1
https://doi.org/10.1002/jnr.24714/v2/response1
Autor:
Serguei Nabirotchkin, Lydie Boussicault, Dirk Czesnik, Susanne Quintes, Jana Zschüntzsch, Jens Schmidt, Julia Adam, David Ewers, Michael Bartl, Daniel Cohen, Julien Laffaire, Karoline Jäger, Klaus-Armin Nave, Anthony Brureau, Markus H. Schwab, Alonso Barrantes-Freer, Stephanie Wernick, Michael W. Sereda, Philippe Rinaudo, Thomas Prukop, Gwenaël Primas, Lorenz Winter, Rodolphe Hajj, Lisa Linhoff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445691622dcc0db7869b1ef4b553b8af
https://doi.org/10.1002/jnr.24679/v2/response1
https://doi.org/10.1002/jnr.24679/v2/response1
Autor:
Jean-Michel Vallat, Claire Demiot, Laurent Magy, Arnaud Lacour, Laurence Richard, Mathilde Duchesne, Tania Stojkovic, Daniel Cohen, Viviane Bertrand, Serguei Nabirotchkin, Pierre-Marie Gonnaud, Klaus-Armin Nave, Yann Péréon, Shahram Attarian, Aurore Danigo
Publikováno v:
Journal of Neuropathology & Experimental Neurology. 77:274-281
Charcot-Marie-Tooth disease type 1A (CMT1A), the most common form of Charcot-Marie-Tooth diseases, is a demyelinating neuropathy caused by a deletion encompassing the gene coding for PMP22, a myelin protein of the peripheral nervous system. Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a34bce535f19bbdda90931c4b2287d91
https://doi.org/10.1093/jnen/nly001
https://doi.org/10.1093/jnen/nly001
Autor:
Philippe Rinaudo, Serguei Nabirotchkin, Jinchao Yu, Alex E. Peluffo, Rodolphe Hajj, Daniel Cohen
Publikováno v:
Current opinion in pharmacology. 51
Drug repurposing has attracted increased attention, especially in the context of drug discovery rates that remain too low despite a recent wave of approvals for biological therapeutics (e.g. gene therapy). These new biological entities-based treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4deef1e97a3bc5677a20a13dda627848
https://pubmed.ncbi.nlm.nih.gov/31982325
https://pubmed.ncbi.nlm.nih.gov/31982325
Autor:
Daniel Cohen, Peter Schmidt, Jacques Touchon, Serguei Nabirotchkin, Robert Philippe, Rene Goedkoop, Sophie Auriacombe, Jacques Hugon, Mickaël Guedj, Jean-Marc Orgogozo, Rodolphe Hajj, Viviane Bertrand, Florence Pasquier, Pierre Jean Ousset, Claude Guériot
Publikováno v:
Alzheimer's & Dementia. 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::212103d47378e0894a51110725a5ecdd
https://doi.org/10.1016/j.jalz.2018.06.063
https://doi.org/10.1016/j.jalz.2018.06.063
Autor:
Rodolphe Hajj, Julie Foucquier, Serguei Nabirotchkin, Daniel Cohen, Niall P. Murphy, Nathalie Cholet, Mickaël Guedj
Publikováno v:
Alzheimer's & Dementia. 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98d9d2348b94de4ba2940da2c5355acf
https://doi.org/10.1016/j.jalz.2017.06.1860
https://doi.org/10.1016/j.jalz.2017.06.1860
Autor:
Daniel Cohen, Jan Stenzel, Magdalena Mroczek, Rodolphe Hajj, Serguei Nabirotchkin, Theresa Kungl, Klaus-Armin Nave, Julia Adam, Stephanie Wernick, Michael W. Sereda, Thomas Prukop, David Ewers
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 1, p e0209752 (2019)
PLoS One
PLoS ONE, Vol 14, Iss 1, p e0209752 (2019)
PLoS One
The most common type of Charcot-Marie-Tooth disease is caused by a duplication of PMP22 leading to dysmyelination, axonal loss and progressive muscle weakness (CMT1A). Currently, no approved therapy is available for CMT1A patients. A novel polytherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1e32fb0a941ee55c1ee9b49feb3c3c
https://doi.org/10.1371/journal.pone.0209752
https://doi.org/10.1371/journal.pone.0209752